

Ceftriaxone/cobicistat/darunavir/hydroxychloroquine

S

Off-label use and lack of efficacy: case report

A 56-year-old man exhibited lack of efficacy during off-label treatment with hydroxychloroquine, cobicistat/darunavir and ceftriaxone for COVID-19 pneumonia [*not all routes stated*].

The man was admitted with COVID-19 pneumonia. Upon admission, he started receiving off-label treatment with hydroxychloroquine 400mg twice a day at day 1 and then 200mg twice a day, cobicistat/darunavir 150/800mg twice a day and IV ceftriaxone 2g once a day. Moreover, he was started on high-flow oxygen therapy. However, despite these treatment his condition worsened rapidly in the first 24 hours after hospitalisation (lack of efficacy). Hence, noninvasive ventilation was started. However, on day 2, his respiratory symptoms worsened further.

Therefore, the man started receiving off-label SC icanitab [Firazyr] 30mg every 8 hours for 3 days for COVID-19 pneumonia. Subsequently, his clinical condition improved, and he was discharged on day 12 without need for supplemental oxygen.

Pecori D, et al. Icatibant in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report. *Journal of Investigational Allergology and Clinical Immunology* 31: 451-452, No. 5, 2021. Available from: URL: <http://doi.org/10.18176/jiaci.0659>

803630169